Compare CYH & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYH | OVID |
|---|---|---|
| Founded | 1985 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.7M | 479.4M |
| IPO Year | 2000 | 2017 |
| Metric | CYH | OVID |
|---|---|---|
| Price | $2.02 | $2.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | $2.51 | ★ $6.15 |
| AVG Volume (30 Days) | 2.2M | ★ 2.5M |
| Earning Date | 10-28-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 196.67 | 3.90 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,485,000,000.00 | $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $2.04 | $1.21 |
| 52 Week High | $3.92 | $3.11 |
| Indicator | CYH | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 33.59 | 39.29 |
| Support Level | $2.04 | $2.12 |
| Resistance Level | $3.04 | $2.67 |
| Average True Range (ATR) | 0.18 | 0.25 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 3.06 | 1.61 |
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.